EGFR

About

Location: 7p11.2

Mappings

HGNC: HGNC:3236

Ensembl: ENSG00000146648

NCBI: 1956

Refseq: NM_005228.5

View API

Biomarkers

EGFR is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
EGFR p.L858R	Somatic variant	10	21
EGFR Exon 19 (Deletion)	Somatic variant	10	21
EGFR activating variants	Somatic variant	1	1
Wild type EGFR	Wild type	27	43
EGFR p.T790M	Somatic variant	2	3
EGFR Somatic variants	Somatic variant	3	4
EGFR Exon 20 (Insertion)	Somatic variant	5	7
EGFR TKD activating variants	Somatic variant	1	1

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organizations	Biomarkers	Cancer types	Therapies
FDA (1) HC (1)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Afatinib
FDA (1) HC (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
FDA (1) HC (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel
FDA (1)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
FDA (1) HC (1)	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed
FDA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR	Non-Small Cell Lung Cancer	Cemiplimab
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Dacomitinib
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Dacomitinib
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib
FDA (1) HC (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Gefitinib
FDA (1) HC (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Gefitinib
FDA (1) HC (2)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (2) HC (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Mobocertinib
FDA (1) HC (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
FDA (3) HC (3)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
FDA (3) HC (3)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
FDA (1) HC (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
FDA (1) HC (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed
FDA (1) HC (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed
FDA (1) HC (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
FDA (1) HC (1)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed
FDA (1) HC (1)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
FDA (2) HC (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
FDA (2) HC (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
FDA (1) HC (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
FDA (1) HC (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed
FDA (1) HC (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
FDA (1) HC (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
HC (1)	EGFR activating variants	Non-Small Cell Lung Cancer	Afatinib
HC (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab
HC (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Cemiplimab
HC (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
HC (1)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
FDA (1)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1)	EGFR p.T790M	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
FDA (1)	EGFR Exon 20 (Insertion)	Invasive Breast Carcinoma	Datopotamab deruxtecan
FDA (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Sunvozertinib
HC (1)	EGFR TKD activating variants	Non-Small Cell Lung Cancer	Gefitinib